Takeda’s commitment to FIRAZYR
What does the patent expiration for FIRAZYR mean?
The patent for FIRAZYR® (icatibant injection) expires on July 15, 2019. After this date, generic options of icatibant may become available. Brand name FIRAZYR will continue to be available.
Takeda remains committed to you and the HAE community
At Takeda, we understand the role that FIRAZYR has played in treating hereditary angioedema (HAE) attacks since 2011.1,2 That’s why we are committed to offering ongoing support for people prescribed FIRAZYR.
- Continued manufacturing and availability of FIRAZYR
- OnePath® will continue to provide product support services to eligible patients (Co-pay assistance is subject to state law)
It is important to note that OnePath can only provide support services for the Takeda HAE product you are prescribed.
Support through OnePath
If you’re enrolled in OnePath, you can reach out to your OnePath Patient Support Manager (PSM) for help with insurance questions, co-pay assistance information, and product support for FIRAZYR
- OnePath is available at 1-866-888-0660, Monday through Friday, 8:30 AM to 8:00 PM ET
How to continue receiving treatment with brand name FIRAZYR
We are making resources available that offer more information about next steps and how to help you continue treatment with brand name FIRAZYR if that is the treatment plan you choose.